



## Myeloma research update – July 2023

Myeloma Canada, along with thousands from the global hematology community, had the privilege of following the [American Society of Clinical Oncology \(ASCO\)](#) Annual Meeting (May 31 – June 4) and attending the [European Hematology Association \(EHA\)](#) Hybrid Congress (June 8-11) to hear from leading myeloma experts about the latest progress in myeloma research.

Once again, similar to our last myeloma research update from the 64th [American Society of Hematology \(ASH\)](#) Annual Meeting and Exposition, the main focus of the myeloma research presented was on chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody treatments.

For a non-exhaustive global overview of the myeloma research presented at both conferences, please consult the following resources by other myeloma patient organizations.

- **International Myeloma Foundation (IMF)**
  - [Top Myeloma Research Presented at ASCO & EHA](#)
  - [2023 Mid-Year Science Update: Entering a New Era of Myeloma Care](#)
- **Multiple Myeloma Research Foundation (MMRF)**
  - [The Latest Myeloma Treatment Advances from ASCO 2023](#)
  - [Updates in Multiple Myeloma from ASCO 2023 for Healthcare Professionals](#)
- **HealthTree Foundation for Multiple Myeloma**
  - [ASCO 2023 Video Playlist](#)

---

For a more specific overview of the latest myeloma research presented at both conferences, below are some resources we've compiled for you.

### Cart T-cell therapies for relapsed/refractory multiple myeloma

- **Ciltacabtagene autoleucel (Cilta-cel; Carvykti)**
  - CARTITUDE-1 (phase 1b/2) trial final results: A median progression-free survival (PFS) of 34.9 months was observed. This is the longest PFS reported in this heavily pretreated patient population.
    - [HealthTree Foundation for Multiple Myeloma](#)
    - [OncLive](#)
    - [Presentation and slides](#)
  - CARTITUDE-4 trial: Cilta-cel vs standard of care PVD or DPd in lenalidomide-refractory multiple myeloma
    - [International Myeloma Foundation](#)
    - [HealthTree Foundation for Multiple Myeloma](#)
    - [Myeloma Patients Europe](#)
    - [Presentation and slides](#)



## CAR T-cell Therapies for Relapsed/Refractory Multiple Myeloma, cont'd.

- **Idecabtagene Vicleucel (Ide-cel; Abecma)**
  - KarMMa-3 trial: Ide-cel vs standard regimens  
International Myeloma Foundation
    - [High-Risk Multiple Myeloma](#)
    - [Health Related Quality of Life](#)
- **Additional CAR T-cell therapies presented (non-exhaustive)**
  - **PHE855**
    - [Shortened manufacturing period from weeks to less than two days](#)
    - [HealthTree Foundation for Multiple Myeloma](#)
  - **BMS-986393 (CC-95266)**
    - [International Myeloma Foundation](#)
  - **LCAR-B38M**
  - **Fast CAR-T GC012F**
  - **CB-011**
  - **IBI346**
  - **Blood Cancer Talks Podcast**

## Bispecific antibody treatments for relapsed/refractory multiple myeloma

- **Teclistamab (TEC; Tectivayli) alone (monotherapy)**
  - MajesTEC-1 trial: Extended follow-up at a median follow-up of 22 months
    - [Poster](#)
    - [Blood Cancers Today](#)
    - [VJHemOnc](#)
- **Teclistamab (TEC; Tectivayli) in combination with nirogacestat or lenalidomide**
  - [MajesTEC-2 \(TEC + nirogacestat\) presentation and slides](#)
  - [MajesTEC-2 \(TEC + lenalidomide\) poster and slide](#)
- **Talquetamab (TAL) alone (monotherapy)**
  - MonumenTAL-1 trial: A phase II study of TAL monotherapy
    - [Myeloma Patients Europe](#)
    - [Slides](#)
- **Teclistamab (TEC; Tectivayli) in combination with talquetamab (TAL)**
  - RedirectTT-1 trial: Dual targeting of relapsed myeloma with TEC and TAL
    - [International Myeloma Foundation](#)
    - [HealthTree Foundation for Multiple Myeloma](#)
    - [Myeloma Patients Europe](#)
    - [Slides](#)



### Bispecific antibody treatments for relapsed/refractory multiple myeloma, cont'd.

- **Teclistamab (TEC; Tecvayli) in combination with talquetamab (TAL)**
  - RedirecTT-1 trial: Dual targeting of relapsed myeloma with TEC and TAL
    - [International Myeloma Foundation](#)
    - [HealthTree Foundation for Multiple Myeloma](#)
    - [Myeloma Patients Europe](#)
    - [Slides](#)
- **Talquetamab (TAL) in combination with daratumumab (DARA; Darzalex)**
  - TRIMM-2 trial: Promising efficacy for the TAL+DARA combination
    - [Targeted Oncology](#)
    - [OnLive](#)
    - [HealthTree Foundation for Multiple Myeloma](#)
    - [Slides](#)
- **Elranatamab**
  - MagnetisMM-3 trial: Extended follow-up and biweekly administration of elranatamab alone (monotherapy)
    - [International Myeloma Foundation](#)
    - [Myeloma Patients Europe](#)
  - Pooled analysis of the MagnetisMM program:
    - [Abstract](#)
    - [HealthTree Foundation for Multiple Myeloma](#)
- **Linvoseltamab (REGN5458) alone (monotherapy)**
  - LINKER-MM1 trial:
    - [International Myeloma Foundation](#)
    - [HealthTree Foundation for Multiple Myeloma](#)
    - [Blood Cancers Today](#)

### Bispecific antibody treatments for relapsed/refractory multiple myeloma Additional treatments

- **Belantamab mafodotin (belamaf; antibody-drug conjugate)**
  - DREAMM-3 trial: Efficacy and safety of belamaf monotherapy (alone) vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
    - [HealthTree Foundation for Multiple Myeloma](#)
  - EMN 27 trial: Efficacy and safety of belantaf monotherapy (alone) in patients with relapsed or refractory light chain (AL) amyloidosis
    - [Myeloma Patients Europe](#)



Bispecific antibody treatments for relapsed/refractory multiple myeloma, additional treatments, cont'd.

- **Selinexor (Xpovio) in relapsed/refractory multiple myeloma**
  - Subgroup data from the BOSTON trial
- **CAEL-101 in amyloid light-chain (AL) amyloidosis**
  - Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain amyloidosis: 18-month results of a phase 2 study
  - Cardiac amyloid reaching for extended survival (cares) trials